

Cortellis


Index and Full Text search

There are different ways of searching in Cortellis: *Index* and *Full Text*. This guide explains how they work and when they should be utilized.

The *Index* option searches fields with controlled vocabulary such as indication, mechanism of action or technology. These fields are designated by the editorial team, according to ontologies in Cortellis. This type of search is available for all report types in *Quick Search* (at the top of every page) and most fields in *Advanced Search*.

Index search is recommended to find results directly associated to your keyword, rather than making a reference to it, e.g. finding results on a specific drug -lacosamide- vs finding competitor drugs that mention lacosamide in their profile.

Example 1: *Index* search “lacosamide” retrieves 4 results corresponding to different formulations of this drug.



The screenshot shows the Cortellis search interface. The search bar contains 'lacosamide' and the 'Index' search type is selected. The results page shows 4 results found for the search term 'lacosamide'. The results are listed in a table with columns for Report Type, Results, Per page, and Sort by. The 'Drugs' category is selected, showing 4 results. A callout box highlights the 'Hit highlighting' feature in the list view, which helps find keywords quicker.

Report Type	Results	Per page	Sort by
Broker Research (4555)	lacosamide Highest Status: Launched Last Change Date: 04-Apr-2021 In September 2014, a single loading dose administration option for all formulations of lacosamide was approved in the US [1726996], [1730656], [1889546].	25	Relevance
Clinical Trials (201)	lacosamide (oral extended release, epilepsy), Adamas Highest Status: Suspended Last Change Date: 23-Mar-2020 Adamas Pharmaceuticals was developing ADS-4101, an extended-release formulation of the CRMP-2 and sodium channel slow inactivation modulator for the potential once-daily oral treatment of partial onset seizures [1726996], [1730656], [1889546].	25	Relevance
Companies (0)		25	Relevance
Conferences (84)		25	Relevance
Deals (4)		25	Relevance
Disease Briefings (1)	lacosamide (oral controlled release, epilepsy), SK Chemicals Highest Status: No Development Reported Last Change Date: 27-Sep-2019 SK Chemicals was investigating SID-1601, a controlled-release formulation of the collapsin response mediator protein 2 (CRMP-2) and sodium channel slow inactivation modulator lacosamide , presumably for the potential once-daily oral treatment of partial onset seizures [1957839].	25	Relevance
Drugs (4)	lacosamide (extended release), BioPharmartis/ Hyundai Highest Status: No Development Reported Last Change Date: 20-Jul-2017 Hyundai Pharmaceutical, together with its affiliate BioPharmartis, was developing BPDO-1602 (formerly BPS-015), a controlled (sustained) release tablet of lacosamide for the potential treatment of epilepsy [1671541], [1746194].	25	Relevance
Event Transcripts (82)		25	Relevance
Literature (942)		25	Relevance
Patents (145)		25	Relevance
Press Releases (287)		25	Relevance

Example 2: *Full Text* search “lacosamide” retrieves 13 results, including other drugs that mention lacosamide in their drug profile or make reference to it as a competitor or related product.

